Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03561584 · ClinicalTrials.gov registry record · Phase 2
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
A Phase 2 study of Primary Sclerosing Cholangitis, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT03561584 is a Phase 2 study of Primary Sclerosing Cholangitis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 32 participants, below the 551-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03561584, a Phase 2 study of Primary Sclerosing Cholangitis, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sulfasalazine
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Chestnut Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2026-03-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03561584
The ClinicalTrials.gov registry entry for NCT03561584 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 551-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (94% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03561584 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03561584 about?
NCT03561584 is a clinical study titled "Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis". This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2)...
What is the current status of trial NCT03561584?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2018-07-01. Estimated completion is 2026-03-03.
What conditions does trial NCT03561584 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis.
What interventions are being tested in trial NCT03561584?
The interventions under investigation include: Placebo (DRUG), Sulfasalazine (DRUG).
Who is sponsoring clinical trial NCT03561584?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03561584 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
RECRUITING · Phase 2
-
Detoxification of the Liver In PSC (Dolphin)
RECRUITING · Phase 2
-
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.